Congratulations to Drs' Kariko and Weissman, our 2022 Ross Prize recipients which is under the umbrella of our journal Molecular Medicine, on their 2023 Nobel Prize in Physiology or Medicine. More information on the Ross Prize in Molecular Medicine can be found here.
Ross Prize in Molecular Medicine
Gerard Honig, Celsius Therapeutics, USA
Douglas Nixon, Weill Cornell Medical College, USA
Johan Sandberg , Karolinska Institute, Sweden
Aims and scope
Molecular Medicine is an open access journal publishing recent findings that elucidate disease pathogenesis at the molecular or physiological level, which may lead to the design of specific tools for disease diagnosis, treatment, or prevention. Manuscripts containing material relevant to the genetic, molecular, or cellular basis of key physiologic or disease processes are considered for publication. Manuscripts submitted to Molecular Medicine should describe the implications of the results for human disease and medicine, at a level approachable by our broad audience.
Criteria to consider for studies involving lnc-RNAs or micro-RNAs:
· As lncRNAs and miRNAs have multiple targets, claims of their function mediated by a single target or pathway will not be accepted, unless multiple additional targets are investigated to support functional specificity.
· The rationale to investigate a specific lncRNA or miRNA needs to be specified upfront in the introduction and justified in the context of other miRNAs known to be functional in that specific field.
· The proposed function of the lnc-RNA or miRNA should be validated by gain and loss of function studies.
· Primary cells should be used whenever possible to confirm findings in cell lines.
· In depth investigation in the signaling pathway(s) regulated by the RNA species should be conducted.
· Insight into the regulation of the RNA species and how it relates to the pathologic state should be provided.
· If applicable: Details of initial screen used to identify RNA species involvement in pathway/disease (number of subjects, statistical tests employed, percent change from controls).
Nobel congratulations to William G. Kaelin Jr
Molecular Medicine is happy to congratulate William G. Kaelin Jr on being a winner of The Nobel Prize in Physiology or Medicine 2019. Professor Kaelin Jr was chosen for his work on the discoveries of how cells sense and adapt to oxygen availability. He previously contributed an article to our journal, "The Molecular Basis of Von Hippel-Lindau Disease", which you can read here.
Molecular Medicine would like to recognize the efforts of the following peer reviewers, for their excellent service during the second quarter of 2023. These individuals have all exceeded expectations as far as acceptance rate, the number of completed reviews, and timeliness. The journal cannot succeed without its peer reviewers, and we thank these hard-working members of our network:
Second Quarter of 2023: Dr. David Chau
Top 10: Most Cited Articles of 2022 and 2021
The semantics of microglia activation: neuroinflammation, homeostasis, and stress
Samuel C. Woodburn, Justin L. Bollinger and Eric S. Wohleb
Inflammation after spinal cord injury: a review of the critical timeline of signaling cues and cellular infiltration
Daniel J. Hellenbrand, Charles M. Quinn, Zachariah J. Piper, Carolyn N. Morehouse, Jordyn A. Fixel & Amgad S. Hanna
The association of neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and lymphocyte to monocyte ratio...
Gong, P., Liu, Y., Gong, Y. et al.
Mer regulates microglial/macrophage M1/M2 polarization and alleviates neuroinflammation following traumatic brain injury
Wu, H., Zheng, J., Xu, S. et al.
Edaravone ameliorates depressive and anxiety-like behaviors via Sirt1/Nrf2/HO-1/Gpx4 pathway
Dang, R., Wang, M., Li, X. et al.
Isoliquiritin ameliorates depression by suppressing NLRP3-mediated pyroptosis via miRNA-27a/SYK/NF-κB axis
Yuanjie Li, Wen Song, Yue Tong, Xia Zhang, Jianjun Zhao, Xiaojuan Gao, Jingjiao Yong & Hanqing Wang
Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies
Edgar Carnero Contentti and Jorge Correale
Uncovering sex differences of rodent microglia
Jinming Han, Yueshan Fan, Kai Zhou, Klas Blomgren & Robert A. Harris
Sirtuin 3 protects against anesthesia/surgery-induced cognitive decline in aged mice by suppressing hippocampal neuroinflammation
Liu, Q., Sun, YM., Huang, H. et al.
Microglia in depression: an overview of microglia in the pathogenesis and treatment of depression
Haixia Wang, Yi He, Zuoli Sun, Siyu Ren, Mingxia Liu, Gang Wang & Jian Yang
Featured cross-journal series: Molecular mechanisms and therapeutic relevance of neuro-immune communication
Our new cross-journal thematic series (published in conjunction with Bioelectronic Medicine), calls for submissions focusing on the molecular mechanisms and therapeutic exploration at the interface between the immune and nervous systems in health and disease and the therapeutic exploration of this insight. It will also cover emerging areas such as the neuronal regulation of hematopoiesis and innate and adaptive immunity. The series is guest edited by Sangeeta Chavan, Colin Reardon, and Niccolò Terrando. Find more information here.
Anthony Cerami Award in Translational Medicine
Molecular Medicine has established the Anthony Cerami Award in Translational Medicine to honor investigators who have created the fundamental innovation necessary for molecular medicine to advance into clinical practice. The award recognizes leading edge discoveries that have led to improvement of human health, and have opened the door to new therapeutic advances and understanding. Find out more.
Ross Prize in Molecular Medicine
The annual Ross Prize in Molecular Medicine is established in conjunction with the Feinstein Institutes for Medical Research and Molecular Medicine. The winner will be an active investigator having produced innovative, paradigm-shifting research that is worthy of significant and broad attention in the field of molecular medicine. Find out more. Please see more information about the 2023 Ross Prize Symposium on Genetic Basis of Lipid Metabolism Disorders here.
Announcing our new article types
Our journal is proud to offer four new article types, ready for submissions!
- Mini-reviews, which provide a concise summary of a specific research topic or field relevant to our scope
- Perspectives, which grants the opportunity to write about the current state and recent developments of a research field or topic within our scope and point to associated challenges and future directions
- Opinions, written with a specific focus on a previously published article which has had a major impact on the field.
- Commentaries, invited pieces which provide further discussion on a primary research manuscript.
Please see our Submission Guidelines page for more.
Molecular Medicine would like to recognize the efforts of the following peer reviewers, for their excellent service during the second quarter of 2023. These individuals have all exceeded expectations as far as acceptance rate, the number of completed reviews, and timeliness. The journal cannot succeed without its peer reviewers, and we thank these hard-working members of our network.
Dr. David Chau - Second Quarter of 2023
About the Editors
Dr Betty Diamond (Editor-in-Chief) graduated with a BA from Harvard University and an MD from Harvard Medical School. She performed a residency in Internal Medicine at Columbia Presbyterian Medical Center and received postdoctoral training in immunology at the Albert Einstein College of Medicine.
Dr Diamond has headed the Rheumatology Divisions at Albert Einstein School of Medicine and at Columbia University Medical Center. She also directed the Medical Scientist Training Program at Albert Einstein School of Medicine for many years. She is currently head of the Center for Autoimmune, Musculoskeletal and Hematopoietic Diseases at The Feinstein Institutes for Medical Research and Director of the PhD and MD/PhD programs at the Zucker School of Medicine at Hofstra-Northwell.
A past president of the American Association of Immunology, Dr Diamond has also served on the Board of Directors of the American College of Rheumatology and the Scientific Council of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
Dr Diamond is a Fellow of the American Association for the Advancement of Science (AAAS) and a member of the National Academy of Medicine.
Valentin Pavlov, The Feinstein Institutes for Medical Research, USA- Executive Editor
Maria Ruggieri, The Feinstein Institutes for Medical Research, USA- Managing Editor
Sonya VanPatten, The Feinstein Institutes for Medical Research, USA- Coordinating Editor
Message from the Editors
What happens when the immune system goes rogue?
In her 2017 TEDMED Talk, Editor-in-Chief Dr Betty Diamond discusses the latest insights in autoimmune disease research, and the pivotal role that patients play in studies.
The Editors of Molecular Medicine welcome authors to send any pre-submission inquiries they might have, here. We ask that you please include “Pre-submission inquiry” in the subject line of your email and that you include the title and abstract of your proposed submission within the message. Our Editors will do their best to respond to you in a timely manner.
If you enjoy Molecular Medicine, we invite you to visit Feinstein’s Bioelectronic Medicine (published by BMC). Bioelectronic Medicine focuses on the regulatory functions of the nervous system and technologies that record, stimulate, or block neural signaling to affect specific molecular mechanisms in health and disease. It also features bioelectronic approaches for monitoring and controlling biological processes and for providing insights into disease pathogenesis that can be utilized in new treatments of inflammatory, neurodegenerative, gastrointestinal, and cardiovascular diseases, paralysis, and many other conditions.
About Feinstein Institutes for Medical Research
Molecular Medicine is published in partnership with The Feinstein Institutes for Medical Research. As the research arm of Northwell Health, the largest healthcare provider in New York, it is home to 50 research laboratories and to clinical research throughout dozens of hospitals and outpatient facilities. The Feinstein Institutes include 4,000 researchers and staff who are making breakthroughs in molecular medicine, genetics, oncology, brain research, mental health, autoimmunity, and bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how the Feinstein Institutes empower imagination and pioneers discovery, visit FeinsteinInstitute.org.
Annual Journal Metrics
Annual Journal Metrics
2022 Citation Impact
5.7 - 2-year Impact Factor
6.3 - 5-year Impact Factor
1.026 - SNIP (Source Normalized Impact per Paper)
1.245 - SJR (SCImago Journal Rank)
8 days submission to first editorial decision for all manuscripts (Median)
122 days submission to accept (Median)
5,337 Altmetric mentions